External botanical care designed for existing milking routines. Raising $3M to complete independent validation, advance the first product to market readiness and prepare for commercial launch.
The problem, the first dairy product, the completed field POC and the next validation step in one focused viewing.
Mastitis creates immediate costs and lasting losses. Treatment remains essential when clinically indicated, yet the space between prevention and medical treatment leaves farms with limited external-care options.
Antibiotics remain necessary when clinically indicated. BotaniSkin is designed to complement veterinary care, never replace or delay it.
Hygiene, nutrition and herd protocols matter, but they do not eliminate mastitis events or the need for workable care options.
Stewardship is tightening while farm economics remain unforgiving. New care must fit the routine and be supported by independent evidence.
Sources: peer reviewed global burden review ($19.7B to $32B); USDA organic dairy guidance. Farm economics vary by herd, geography and management.
The field POC demonstrated routine integration. The next study will quantify application time, labor and training burden, adherence and workflow disruption.
The first product comes first. This round is focused on bovine udder care, independent evidence and launch readiness. The formulation, manufacturing process and field workflow may support broader platform opportunities only after the first product is de-risked. Human health applications remain exploratory and are outside this round.
Product development, botanical manufacturing, veterinary fieldwork and commercial execution are integrated within a single operating team.
A field POC on a commercial Israeli dairy demonstrated production and operational feasibility. BotaniSkin integrated the product into the farm’s existing routine and observed positive results in use. This was not a controlled efficacy study. The next step is independent controlled validation to confirm, quantify and document the findings.
A focused beachhead creates a practical route to design partners, independent evidence and first paid deployments without narrowing the long-term opportunity.
The sequence: validate with larger U.S. design partners, complete the independent evidence gate, prepare the market-specific pathway and begin first paid deployments before selected expansion.
Under U.S. organic regulations, medically necessary treatment cannot be withheld. Once a dairy cow is treated with antibiotics, products from that animal can no longer be marketed as organic. This creates a clear economic need for practical, evidence-based udder care that integrates into existing farm routines.
Sources: USDA ERS organic dairy report; 7 CFR §205.238. Market sequencing remains subject to evidence and market-specific review.
Defensibility is built through independent evidence, proprietary know-how and a repeatable path to controlled manufacturing.
Controlled validation, operational adoption data and market-specific records will strengthen the first-product position.
BotaniSkin develops and operates its proprietary formulation and manufacturing process in-house.
The manufacturing workstream is designed to improve repeatability, quality control and transferability.
A premix architecture is being prepared for future industrial manufacturing.
Current protection: proprietary trade-secret formulation and manufacturing process. Patent strategy: PCT filing in development. Legal counsel: Herzog Fox & Neeman. IP counsel: Luzzatto & Luzzatto.
Four workstreams. One objective: independent validation and commercial readiness.
Completed on a commercial Israeli dairy farm, demonstrating field feasibility and positive results under farm conditions.
Run independent controlled validation and larger design-partner deployments while advancing manufacturing and market-specific regulatory readiness.
Begin first paid U.S. deployments, establish repeatable farm economics and expand selectively after evidence.
This round offers the opportunity to invest before independent validation and the first commercial launch. We are looking for investors and strategic partners who can help move BotaniSkin from demonstrated field feasibility to commercial scale.